Ivonescimab for Adrenocortical Carcinoma

This trial aims to determine if ivonescimab, a potential new drug, can help manage adrenocortical carcinoma (ACC) or pheochromocytoma and paraganglioma (PPGL) that have spread or recurred after other treatments. The study will assess how effectively this treatment controls these cancers. This trial may suit individuals with confirmed ACC or PPGL that has progressed and is not suitable for surgery. As a Phase 2 trial, the research focuses on evaluating the treatment's effectiveness in an initial, smaller group of participants.

Research has shown that ivonescimab generally has a manageable safety profile. In previous studies, about 14.6% of patients experienced serious side effects, known as Grade 3–4 adverse events, including low white blood cell counts and lung inflammation. However, these effects are similar to those expected from other treatments and can usually be managed.

Ivonescimab is unique because it represents a novel approach to treating adrenocortical carcinoma (ACC) by specifically targeting cancer cells. While most standard treatments for ACC, like mitotane or chemotherapy, rely on broadly attacking rapidly dividing cells, ivonescimab works by harnessing and enhancing the body's own immune system to fight cancer more precisely. Researchers are particularly excited about its potential to reduce side effects and improve outcomes by focusing the treatment on the tumor cells while sparing healthy ones. This targeted action could lead to more effective and personalized treatment options for patients with ACC.

Research has shown that ivonescimab yields promising results for cancer patients. In studies on non-small cell lung cancer, ivonescimab treatments significantly improved the disease control rate (DCR) compared to traditional chemotherapy. Specifically, patients receiving ivonescimab lived longer on average, with a survival time of 27.9 months compared to 23.7 months for those in the control group. The treatment also extended the period during which the cancer did not worsen. This trial will evaluate ivonescimab for adrenocortical carcinoma (ACC), and these findings suggest that ivonescimab could effectively manage advanced cancers like ACC.¹⁶⁷⁸⁹